The following table is intended to give investigators an idea of what their responsibilities will be in the event a decision is made to pursue a study through Takeda's II-SR Program. Takeda desires to communicate these responsibilities to potential investigators prior to their submission of a new concept to enable investigators to make a confidential commitment of his/her time and resources to conduct the research study.
Task/Methodology |
Deliverables |
Time Period Due |
New Concept:
|
|
|
New Protocol:
|
|
Within four (4) months from receipt of the New Concept notification letter (informing investigator that his/her New Concept merits submission of a New Protocol), the complete protocol will be submitted |
Fair Market Value: Acceptance of documented industry fair market value for services
|
Budget for study reflecting fair market value |
Prior to Study Agreement (contract) initiation |
Study Agreement: Review of draft Study Agreement, requested changes, and approve/sign fully negotiated Study Agreement
|
Executed Study Agreement |
Within three (3) months of Takeda's acceptance of the New Protocol |
Regulatory Documents
|
|
Within four (4) months from Takeda's acceptance of the New Protocol |
Clinical Registry (if required): Register clinical study as the Sponsor on www.ClinicalTrials.gov Please note: Takeda is NOT the sponsor
|
On Takeda's II-SR website, check the box indicating completed and clinicaltrials.gov number inserted into website |
Prior to initial milestone payment or shipment of drug |
Enrollment/Progress Report:**
|
|
|
Invoicing (if applicable): Submit appropriate payment requests through the Takeda website
|
Payment request |
Upon completion of each milestone per the Study Agreement |
Drug/Clinical Supply Accountability (if applicable):
|
|
|
Close-out of Study:
|
Final documents
|
|
** Please also reference the additional information found in the Study Management section of this guide.
